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tolerance levels and mean value and standard deviation four 
field box cases were +0.68%±2.43%(1SD). 
 
Conclusion: It was noticed that standard deviation for both 
patient groups was similar and that initial tolerance/action 
levels for pelvic cases were substantial. Also, the five fields 
technique with wedges showed good results due to uniform 
directional response around diode axis. Within one year after 
implementation, in vivo dosimetry has revealed and 
prevented 6 cases of inaccurate treatment. In our 
experience, systematic in vivo dosimetry proved to be a very 
useful tool for quality assurance of a patient plan and 
treatment, both in detecting systematic errors and for 
estimating the accuracy of radiotherapy treatment delivery. 
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Purpose or Objective: Brachytherapy HDR treatments are 
performed according to the plans calculated with the 
computerized treatment planning systems. The source 
positions and dwell times are established to produce required 
dose distributions. However, in general, the treatment plans 
are not verified. A phantom for such dose distribution 
verification is proposed to be used with the ArcCHECK 
system. 
 
Material and Methods: The ArcCHECK detector array and the 
SNC Patient software were designed by Sun Nuclear to verify 
dose distributions in the IMRT and VMAT external beam 
therapy. It is a cylindrical tissue-equivalent phantom, 
containing 3D detector array, consisting of 1386 SunPoint 
diodes. The detectors are located helically along the cylinder 
with the external diameter of 21 cm. We believe that the 
ArcCHECK phantom could also be used to verify the 
brachytherapy dose calculations. For this purpose a special 
additional part of PMMA, a Brachyplug, was designed and 
manufactured. The Brachyplug is a special cylinder installed 
inside the ArcCHECK in which it is possible to place 
dosimetric films or ionization chambers. The phantom has a 
number of through holes, where the HDR catheters can be 
placed into which the Ir-192 stepping source may enter. A 
special brachytherapy plan was created using the Ocentra 
MasterPlan planning system with 4 source positions in order 
to create evenly distributed dose over the detectors of the 
ArcCHECK array. In order to check the amount of dose which 
could be absorbed by the electronics of the ArcCHECK system 
the doses at the relevant distance were measured with the 
PTW dosimeter and a Farmer type 30013 ionization chamber 
placed in PTW RW3 plate phantom under the Brachyplug. The 
measurements were carried out with and without a shield, a 
8 cm thick Wood alloy plug, designed in order to protect the 
electronic control unit of the ArcCHECK from irradiation. 
After that the dose distribution for the planned source 
positions was measured with ArcCHECK device with 8 cm 
thick Wood alloy plug and Brachyplug placed inside the 
ArcCHECK cylinder. 
 
Results: Measurements of irradiation according to the 
prepared plan indicate that when the ArcCHECK detectors 
obtain the dose of 1 Gy the total dose which could reach the 
ArcCHECK electronics is 12.7 cGy. Such dose is acceptable 
and similar to the dose in a case of teletherapy. The 
ArcCHECK allowed for detecting and displaing in the SNC 
Patient software the HDR brachytherapy irradiation 
distributions. 
 
Conclusion: The ArcCHECK device may be potentially used 
for pretreatment verification of dose distributions in 
brachytherapy. This would require the development of proper 
energy calibration procedure for the ArcCHECK detectors and 
the SNC Patient software update. The Brachyplug phantom 
will be used for further research on verification of clinical 
treatment plans in brachytherapy. 
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Purpose or Objective: The IQM is an innovative wedge 
shaped transmission ion chamber which is mounted below the 
front face of a Linac head. It monitors the total radiation 
fluence coming from the treatment head (see figure). It is 
currently undergoing Beta-testing to monitor and verify the 
delivery of individual treatment fields in real-time. Its 
potential as a tool for Linac quality control measurements is 
also being investigated. 
 
Material and Methods: Over an 11 month period a series of 
QC and clinical prescriptions were delivered multiple times to 
the IQM mounted on an Elekta VersaHD Linac, to evaluate its 
sensitivity to potential clinical errors and its long-term 




IQM mounted on Linac, with schematic of detector design  
Results: The device proved reliable over the testing period. 
It’s stability and reproducibility are shown in the table. 
Measurements showed that MLC/Jaw mis-calibrations of 2mm 
could be identified, as could 2% errors in MU. A change of 
energy from 6MV to 10MV gave a difference in IQM signal of 
6% for conformal and ‘step and shoot’ IMRT, and of 2-4% for 
VMAT deliveries. Seventeen similar VMAT head and neck 
plans each demonstrated a unique IQM signal vs control point 
pattern, potentially allowing an incorrect plan, or ‘plan of 
the day’ to be identified after only 40 degrees of the arc. 
The IQM was able to identify clinically significant flatness, 
symmetry and output errors on the Linac. 
Modality Beam Description Standard Deviation 
Static field 10x10cm @6MV 0.7% 
Static field 4x4cm @6MV 1.0% 
Conformal Arc 10x10cm @6MV 0.8% 
IMRT Step & Shoot @6MV &10MV 0.7% 
Simple VMAT Prostate VMAT @10MV 0.8% 
Complex VMAT Head and Neck VMAT @6MV 1.1% 
Variation in IQM signal over 11 months for different 
modalities  
 
Conclusion: Although the IQM is still under development it 
can identify a number of clinically significant potential errors 
in treatment delivery. It is easy to use ‘on set’ and has 
proved stable and reliable. It has the potential for use as a 
